Want to see DXCM full AI Analyst Report?
DXCM Stock Chart & Stats
$63.98
$0.53(0.67%)
At close: 4:00 PM EST
$63.98
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $89.98
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.86M
Market Cap
$29.21B
Enterprise Value$23.69K
Total Cash (Recent Filing)$2.42B
Total Debt (Recent Filing)$1.38B
Price to Earnings (P/E)31.5
Beta1.09
Next Earnings
Jul 30, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding385,873,000
10 Day Avg. Volume4,697,748
30 Day Avg. Volume4,857,262
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$84.00Price Target Upside31.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)2.59
Revenue Forecast (FY)$5.22B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueDexcom’s core business is a durable consumables model: regularly replaced sensors and periodic transmitters create annuity-like demand from an installed base. That structural recurring revenue supports predictable top-line, higher lifetime customer value, and resilience versus one-time device sales.
Sustained Margin ExpansionMaterial margin improvement reflects scalable manufacturing, pricing power, and operating leverage as volumes and efficiencies grow. Higher and expanding gross and operating margins bolster free cash flow potential and fund R&D and commercial investments without diluting returns.
Strong Cash Generation & Balance SheetRobust operating and free cash flow combined with a solid cash buffer and reduced leverage improves financial flexibility. This supports reinvestment, M&A optionality, share repurchases, and weathering reimbursement timing, enhancing long-term strategic optionality and capital allocation.
Bears Say
Reimbursement And Tender DependenceDurable growth depends on broad payer coverage; uncertain CMS timing leaves a large U.S. segment inaccessible for now. International expansion also relies on country tenders, which are lumpy. Both reimbursement and tender dynamics create sustained visibility risk for adoption and revenue.
Input-cost And Ramp Pressure On MarginsExposure to commodity and logistics inputs can structurally compress gross margins if costs persist. Simultaneous investments and Ireland manufacturing ramp will elevate near-term operating spend, testing the durability of recent margin gains unless offset by productivity or pricing.
Market Moderation And CompetitionStructural competition and a potentially moderating U.S. CGM market increase the need to sustain new patient starts and product conversions. Slower organic adoption or stronger competitor moves would pressure revenue growth and require higher sales/marketing or product differentiation to maintain share.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $89.98 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $29.21B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 30, 2026. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.466 by $0.094.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.61.
How many shares outstanding does Dexcom have?
Dexcom has 385,873,000 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.56 in its last earnings report, beating expectations of $0.466. Following the earnings report the stock price went up 3.023%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.00 (31.29% Upside)
$84.00 (31.29% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 421.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DXCM Revenue Breakdown
71.53% U.S.
28.47% International
DXCM Stock 12 Month Forecast
Average Price Target
$84.00
▲(31.29% Upside)
Technical Analysis
Ownership Overview
0.42% Insiders
25.80% Mutual Funds
1.18% Other Institutional Investors
38.25% Public Companies and Individual Investors